Abstract
The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has triggered a global effort to rapidly develop and deploy effective and safe coronavirus disease 2019 (COVID-19) vaccinations. Vaccination has been one of the most effective medical interventions in human history, although potential safety risks of novel vaccines must be monitored, identified, and quantified. Adverse events must be carefully assessed to define whether they are causally associated with vaccination or coincidence. Neurologic adverse events following immunizations are overall rare but with significant morbidity and mortality when they occur. Here, we review neurologic conditions seen in the context of prior vaccinations and the current data to date on select COVID-19 vaccines including mRNA vaccines and the adenovirus-vector COVID-19 vaccines, ChAdOx1 nCOV-19 (AstraZeneca) and Ad26.COV2.S Johnson & Johnson (Janssen/J&J).
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference61 articles.
1. SARS-CoV-2 vaccines in development
2. Adverse Events Associated With Childhood Vaccines Other Than Pertussis and Rubella
3. WHO. Adverse events following immunization (AEFI). Accessed February 17, 2020. who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance/health-professionals-info/aefi
4. Annual Summary of Vital Statistics: Trends in the Health of Americans During the 20th Century
5. Paralytic poliomyelitis: United States, 1980-1994;CDC;MMWR Morb Mortal Wkly Rep.,1997
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献